Telbivudine
INDICATIONS
FDA
FDA
Historical FDA indication: Chronic hepatitis B with evidence of viral replication and either persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: November 7, 2026
Citation
Auwaerter, Paul G. "Telbivudine." Johns Hopkins HIV Guide, The Johns Hopkins University, 2026. Johns Hopkins Guides, www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545198/all/Telbivudine.
Auwaerter PG. Telbivudine. Johns Hopkins HIV Guide. The Johns Hopkins University; 2026. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545198/all/Telbivudine. Accessed November 17, 2026.
Auwaerter, P. G. (2026). Telbivudine. In Johns Hopkins HIV Guide. The Johns Hopkins University. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545198/all/Telbivudine
Auwaerter PG. Telbivudine [Internet]. In: Johns Hopkins HIV Guide. The Johns Hopkins University; 2026. [cited 2026 November 17]. Available from: https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545198/all/Telbivudine.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Telbivudine
ID - 545198
A1 - Auwaerter,Paul,M.D.
Y1 - 2026/11/07/
BT - Johns Hopkins HIV Guide
UR - https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545198/all/Telbivudine
PB - The Johns Hopkins University
DB - Johns Hopkins Guides
DP - Unbound Medicine
ER -

Johns Hopkins HIV Guide

